Close Menu

NEW YORK— HTG Molecular Diagnostics reported after the close of the market on Tuesday that its first quarter revenues dropped 66 percent year over year.

For the three months ended June 30, the Tucson, Arizona-based firm reported revenues of $2.0 million compared to $5.8 million in the same period the year before, beating the Wall Street estimate of $1.8 million. The firm attributed the decrease to the impact of the COVID-19 pandemic, which required the closure of customer facilities around the globe during the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.